Moderna and Samsung Biologics Partner on Fill/Finish Manufacturing of Moderna’s COVID-19 Vaccine

BioPharm International Editors

Samsung Biologics plans to support the production of hundreds of millions of doses of Moderna’s vaccine to supply to markets outside of the United States beginning in the third quarter of 2021.

Moderna and Samsung Biologics announced on May 22, 2021 that they have entered into a manufacturing services and supply agreement under which Samsung Biologics will provide large scale, commercial fill/finish manufacturing for mRNA-1273, Moderna’s COVID-19 vaccine.

Under the terms of the agreement, technology transfer will take place at Samsung Biologics’ Incheon, South Korea, facilities where it will utilize its production line designed for aseptic fill/finish, labeling, and packaging, Moderna said in a company press release. Samsung Biologics plans to support the production of hundreds of millions of doses of the vaccine to supply to markets outside of the United States beginning in the third quarter of 2021.

“This vaccine is paramount to people around the world in the fight against the COVID-19 pandemic, and we truly appreciate our client Moderna for entrusting and choosing to partner with Samsung Biologics for the fill and finish of this important vaccine,” said John Rim, CEO of Samsung Biologics, in the press release. “Due to the high level of urgency in supplying the vaccine to the global population, we have set immediate action plans and schedule to make mRNA-1273 available for commercial distribution in the early second half of 2021.”

“We are pleased to partner with Samsung Biologics for this fill and finish manufacturing, which will help us continue to scale up our manufacturing capacity outside of the US,” said Juan Andres, Moderna’s chief technical operations and quality officer, in the press release. “We and our manufacturing partners remain committed to defeating the COVID-19 pandemic.”

Source: Moderna